Search research articles
Contact Us
Filters
Showing results (81-90 of 104) with videos related to
Page
of 11
Sort By:
Frontiers in Oncology
|
June 10, 2021
Early Exanthema Upon Vemurafenib Plus Cobimetinib Is Associated With a Favorable Treatment Outcome in Metastatic Melanoma: A Retrospective Multicenter DeCOG Study
Katharina C Kähler, Ralf Gutzmer, Friedegrund Meier, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
March 22, 2025
Early termination does not negatively impact the outcome of adjuvant immunotherapy in melanoma
Dirk Tomsitz, Elisabeth Livingstone, Carmen Loquai, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 6, 2017
Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis
Sandra P D'Angelo, James Larkin, Jeffrey A Sosman, et al.
The Lancet. Oncology
|
May 19, 2015
Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial
Michael R Migden, Alexander Guminski, Ralf Gutzmer, et al.
Journal of the American Academy of Dermatology
|
April 13, 2016
The 12-month analysis from Basal Cell Carcinoma Outcomes with LDE225 Treatment (BOLT): A phase II, randomized, double-blind study of sonidegib in patients with advanced basal cell carcinoma
Reinhard Dummer, Alexander Guminski, Ralf Gutzmer, et al.
Cancers
|
June 2, 2021
Discontinuation of BRAF/MEK-Directed Targeted Therapy after Complete Remission of Metastatic Melanoma-A Retrospective Multicenter ADOReg Study
Henner Stege, Maximilian Haist, Michael Schultheis, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 26, 2026
Treatment patterns in geriatric patients with melanoma and the effect of age on the efficacy of immunotherapy: Analysis from the real-world multicenter registry ADOREG
Konstantinos Lallas, Lena Nanz, Selma Ugurel, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 28, 2025
Real-world experience with first- versus second-line cemiplimab for advanced basal cell carcinoma
Viola K DeTemple, Martin Kaatz, Eggert Stockfleth, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 28, 2023
Immune checkpoint inhibition in patients with NRAS mutated and NRAS wild type melanoma: a multicenter Dermatologic Cooperative Oncology Group study on 637 patients from the prospective skin cancer registry ADOREG
Anne Zaremba, Peter Mohr, Ralf Gutzmer, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 25, 2019
Safety and efficacy of nivolumab in patients with rare melanoma subtypes who progressed on or after ipilimumab treatment: a single-arm, open-label, phase II study (CheckMate 172)
Paul Nathan, Paolo A Ascierto, John Haanen, et al.
Page
of 11
Search research articles
Search
Showing results (81-90 of 104) with videos related to
Sort By:
Page
of 11
Frontiers in Oncology
|
June 10, 2021
Early Exanthema Upon Vemurafenib Plus Cobimetinib Is Associated With a Favorable Treatment Outcome in Metastatic Melanoma: A Retrospective Multicenter DeCOG Study
Katharina C Kähler, Ralf Gutzmer, Friedegrund Meier, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
March 22, 2025
Early termination does not negatively impact the outcome of adjuvant immunotherapy in melanoma
Dirk Tomsitz, Elisabeth Livingstone, Carmen Loquai, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 6, 2017
Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis
Sandra P D'Angelo, James Larkin, Jeffrey A Sosman, et al.
The Lancet. Oncology
|
May 19, 2015
Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial
Michael R Migden, Alexander Guminski, Ralf Gutzmer, et al.
Journal of the American Academy of Dermatology
|
April 13, 2016
The 12-month analysis from Basal Cell Carcinoma Outcomes with LDE225 Treatment (BOLT): A phase II, randomized, double-blind study of sonidegib in patients with advanced basal cell carcinoma
Reinhard Dummer, Alexander Guminski, Ralf Gutzmer, et al.
Cancers
|
June 2, 2021
Discontinuation of BRAF/MEK-Directed Targeted Therapy after Complete Remission of Metastatic Melanoma-A Retrospective Multicenter ADOReg Study
Henner Stege, Maximilian Haist, Michael Schultheis, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 26, 2026
Treatment patterns in geriatric patients with melanoma and the effect of age on the efficacy of immunotherapy: Analysis from the real-world multicenter registry ADOREG
Konstantinos Lallas, Lena Nanz, Selma Ugurel, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 28, 2025
Real-world experience with first- versus second-line cemiplimab for advanced basal cell carcinoma
Viola K DeTemple, Martin Kaatz, Eggert Stockfleth, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 28, 2023
Immune checkpoint inhibition in patients with NRAS mutated and NRAS wild type melanoma: a multicenter Dermatologic Cooperative Oncology Group study on 637 patients from the prospective skin cancer registry ADOREG
Anne Zaremba, Peter Mohr, Ralf Gutzmer, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 25, 2019
Safety and efficacy of nivolumab in patients with rare melanoma subtypes who progressed on or after ipilimumab treatment: a single-arm, open-label, phase II study (CheckMate 172)
Paul Nathan, Paolo A Ascierto, John Haanen, et al.
Page
of 11